Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Sep 25 - Sep 30
COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments
Primary Care Oncology
TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes
These outcomes matter for long-term health and mortality and should not be overshadowed by aesthetic or weight-loss narratives
The use of total effect indices negates the need for determining higher order interactions which can be computationally expensive
US$ 24.91
US$ 25.85
US$ 28.04
